MGO One Seven LLC Has $502,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

MGO One Seven LLC cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 10.4% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,697 shares of the biopharmaceutical company’s stock after selling 781 shares during the quarter. MGO One Seven LLC’s holdings in Gilead Sciences were worth $502,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bank Julius Baer & Co. Ltd Zurich raised its holdings in shares of Gilead Sciences by 98,797.6% in the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 394,005,889 shares of the biopharmaceutical company’s stock valued at $30,366,034,000 after acquiring an additional 393,607,491 shares in the last quarter. Capital World Investors lifted its stake in shares of Gilead Sciences by 5.8% in the 2nd quarter. Capital World Investors now owns 80,929,316 shares of the biopharmaceutical company’s stock valued at $6,237,075,000 after purchasing an additional 4,429,076 shares during the period. State Street Corp increased its holdings in shares of Gilead Sciences by 2.6% in the 2nd quarter. State Street Corp now owns 59,317,162 shares of the biopharmaceutical company’s stock worth $4,571,574,000 after purchasing an additional 1,514,894 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Gilead Sciences by 1.9% in the second quarter. Geode Capital Management LLC now owns 24,212,636 shares of the biopharmaceutical company’s stock valued at $1,861,363,000 after acquiring an additional 447,585 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its stake in Gilead Sciences by 324.8% in the first quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock worth $1,070,232,000 after purchasing an additional 13,764,169 shares in the last quarter. 82.33% of the stock is currently owned by institutional investors.

Gilead Sciences Trading Down 0.9 %

Gilead Sciences stock traded down $0.71 during midday trading on Friday, hitting $79.52. 5,366,183 shares of the stock were exchanged, compared to its average volume of 7,558,327. The company has a quick ratio of 1.20, a current ratio of 1.34 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a 52 week low of $72.87 and a 52 week high of $87.86. The company has a fifty day simple moving average of $80.44 and a two-hundred day simple moving average of $78.25. The stock has a market capitalization of $99.09 billion, a PE ratio of 17.10, a P/E/G ratio of 0.95 and a beta of 0.24.

Gilead Sciences (NASDAQ:GILDGet Free Report) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.38. The business had revenue of $7.05 billion for the quarter, compared to the consensus estimate of $6.81 billion. Gilead Sciences had a net margin of 21.45% and a return on equity of 39.30%. The firm’s revenue for the quarter was up .1% on a year-over-year basis. During the same period in the previous year, the company earned $1.90 earnings per share. Equities research analysts anticipate that Gilead Sciences, Inc. will post 6.77 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 15th were paid a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a yield of 3.77%. The ex-dividend date of this dividend was Thursday, December 14th. Gilead Sciences’s payout ratio is 64.38%.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. UBS Group dropped their target price on Gilead Sciences from $85.00 to $84.00 and set a “neutral” rating on the stock in a report on Wednesday, November 8th. Leerink Partnrs reaffirmed a “market perform” rating on shares of Gilead Sciences in a report on Wednesday, October 11th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Gilead Sciences in a report on Thursday, November 9th. They issued a “hold” rating and a $75.00 target price for the company. StockNews.com assumed coverage on shares of Gilead Sciences in a research note on Thursday, October 5th. They set a “strong-buy” rating for the company. Finally, Barclays raised their price objective on shares of Gilead Sciences from $82.00 to $85.00 and gave the stock an “equal weight” rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences currently has an average rating of “Hold” and an average target price of $87.20.

Get Our Latest Research Report on Gilead Sciences

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 8,242 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $85.23, for a total transaction of $702,465.66. Following the completion of the transaction, the insider now owns 82,729 shares in the company, valued at approximately $7,050,992.67. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CFO Andrew D. Dickinson sold 5,000 shares of Gilead Sciences stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $85.78, for a total value of $428,900.00. Following the completion of the sale, the chief financial officer now owns 101,534 shares of the company’s stock, valued at approximately $8,709,586.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Johanna Mercier sold 8,242 shares of Gilead Sciences stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $85.23, for a total transaction of $702,465.66. Following the completion of the sale, the insider now directly owns 82,729 shares of the company’s stock, valued at approximately $7,050,992.67. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.

See Also

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDFree Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.